Next-generation Models for the PK Evaluation of Antibody and Albumin-Conjugated Drug Candidates

April 2, 2025, 4:30 PM CEST | 3:30 PM (BST)
10:30 AM ET (New York)
(Convert this to your time zone)

Conventional preclinical models often fail to evaluate antibody-based therapeutics, as they do not reflect crucial aspects of human physiology, forcing drug developers to adopt cautious and complex strategies. JAX's next-generation humanized models offer a solution by faithfully reproducing human physiology and pathology. These models enable more accurate predictions of biologic drug candidate performance, providing more predictive preclinical PK data.

Join our upcoming virtual symposium to explore how JAX's humanized models enable rational selection of the best lead therapeutic candidates, with equivalent or better predictive ability than nonhuman primates for human pharmacokinetics. The symposium will consist of three 20-minute presentations. Details are listed below.

Join us as we discuss:

Paste Bullet 1 Here in the HTML Editor
Paste Bullet 2 Here in the HTML Editor
Paste Bullet 3 Here in the HTML Editor
Paste Bullet 4 Here in the HTML Editor

This virtual event is complimentary.
No fees will be charged for registering.

When registering, please use an institutional (e.g. work, university, etc.) email address or contact our event staff to request an exception. Thank you.

Agenda & Presentation Details

Opening Remarks and Introduction

Adriano Flora, Ph.D.

Director, Business Development – Europe

The Jackson Laboratory

Humanized FcRn mouse model for evaluating PK and allometric scaling

Monika Gajewska, Ph.D.

M&S Group, PK Sciences

Novartis Pharma AG

Use of the Tg32 model to analyze antibody PK

Martin Lechmann Ph.D.

DMPK/PD Project Lead (DPL) Biologics

Roche Diagnostics GmbH

The huAlbTg32 model to study the PK and distribution of albumin-conjugated molecules

Jan Terje Andersen, Ph.D.

Professor in Biomedical Innovation

University of Oslo

Biology-Guided Engineering of Human Albumin Fusion Proteins: From Cross-Species Studies to Proof-Of-Concept in Transgenic Mouse Models

Kristin Hovden Aaen, Ph.D.

Postdoc in the Laboratory of Adaptive Immunity and Homeostasis

University of Oslo and Oslo University Hospital